Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Aberrant miRNAs expressed in HER-2 negative breast cancers patient.

Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I.

J Exp Clin Cancer Res. 2018 Oct 20;37(1):257. doi: 10.1186/s13046-018-0920-2.

2.

Molecular Responses of Cancers by Natural Products: Modifications of Autophagy Revealed by Literature Analysis.

Yeung AWK, El-Demerdash A, Berindan-Neagoe I, Atanasov AG, Ho YS.

Crit Rev Oncog. 2018;23(5-6):347-370. doi: 10.1615/CritRevOncog.2018027566.

PMID:
30311565
3.

Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.

Selicean SE, Tomuleasa C, Grewal R, Almeida-Porada G, Berindan-Neagoe I.

Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1516881. [Epub ahead of print]

PMID:
30277128
4.

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge.

Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I.

J Breast Cancer. 2018 Sep;21(3):233-243. doi: 10.4048/jbc.2018.21.e41. Epub 2018 Sep 20. Review.

5.

Exosomes at a glance - common nominators for cancer hallmarks and novel diagnosis tools.

Gulei D, Petrut B, Tigu AB, Onaciu A, Fischer-Fodor E, Atanasov AG, Ionescu C, Berindan-Neagoe I.

Crit Rev Biochem Mol Biol. 2018 Oct;53(5):564-577. doi: 10.1080/10409238.2018.1508276. Epub 2018 Sep 24.

PMID:
30247075
6.

Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.

Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I.

Crit Rev Clin Lab Sci. 2018 Sep 21:1-15. doi: 10.1080/10408363.2018.1499707. [Epub ahead of print]

PMID:
30238808
7.

Correction: Genetically enhanced T lymphocytes and the intensive care unit.

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.

Oncotarget. 2018 Aug 10;9(62):32097. doi: 10.18632/oncotarget.25983. eCollection 2018 Aug 10.

8.

OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.

Monroig-Bosque PDC, Shah MY, Fu X, Fuentes-Mattei E, Ling H, Ivan C, Nouraee N, Huang B, Chen L, Pileczki V, Redis RS, Jung EJ, Zhang X, Lehrer M, Nagvekar R, Mafra ACP, Monroig-Bosque MDM, Irimie A, Rivera C, Dan Dumitru C, Berindan-Neagoe I, Nikonowicz EP, Zhang S, Calin GA.

Sci Rep. 2018 Aug 30;8(1):13106. doi: 10.1038/s41598-018-30989-3.

9.

Combined Therapy in Cancer: The Non-coding Approach.

Gulei D, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2018 Sep 7;12:787-792. doi: 10.1016/j.omtn.2018.07.013. Epub 2018 Jul 31. No abstract available.

10.

Phytol: A review of biomedical activities.

Islam MT, Ali ES, Uddin SJ, Shaw S, Islam MA, Ahmed MI, Chandra Shill M, Karmakar UK, Yarla NS, Khan IN, Billah MM, Pieczynska MD, Zengin G, Malainer C, Nicoletti F, Gulei D, Berindan-Neagoe I, Apostolov A, Banach M, Yeung AWK, El-Demerdash A, Xiao J, Dey P, Yele S, Jóźwik A, Strzałkowska N, Marchewka J, Rengasamy KRR, Horbańczuk J, Kamal MA, Mubarak MS, Mishra SK, Shilpi JA, Atanasov AG.

Food Chem Toxicol. 2018 Nov;121:82-94. doi: 10.1016/j.fct.2018.08.032. Epub 2018 Aug 18.

PMID:
30130593
11.

Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death.

Chira S, Raduly L, Braicu C, Jurj A, Cojocneanu-Petric R, Pop L, Pileczki V, Ionescu C, Berindan-Neagoe I.

Exp Ther Med. 2018 Aug;16(2):1241-1249. doi: 10.3892/etm.2018.6324. Epub 2018 Jun 19.

12.

Differential Effect of Smoking on Gene Expression in Head and Neck Cancer Patients.

Irimie AI, Braicu C, Cojocneanu R, Magdo L, Onaciu A, Ciocan C, Mehterov N, Dudea D, Buduru S, Berindan-Neagoe I.

Int J Environ Res Public Health. 2018 Jul 23;15(7). pii: E1558. doi: 10.3390/ijerph15071558.

13.

Overview upon miR-21 in lung cancer: focus on NSCLC.

Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I.

Cell Mol Life Sci. 2018 Oct;75(19):3539-3551. doi: 10.1007/s00018-018-2877-x. Epub 2018 Jul 20. Review.

PMID:
30030592
14.

Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.

Nabavi SF, Atanasov AG, Khan H, Barreca D, Trombetta D, Testai L, Sureda A, Tejada S, Vacca RA, Pittalà V, Gulei D, Berindan-Neagoe I, Shirooie S, Nabavi SM.

Cancer Lett. 2018 Oct 10;434:101-113. doi: 10.1016/j.canlet.2018.07.018. Epub 2018 Jul 17.

PMID:
30030139
15.

A miRNAs profile evolution of triple negative breast cancer cells in the presence of a possible adjuvant therapy and senescence inducer.

Lajos R, Braicu C, Jurj A, Chira S, Cojocneanu-Petric R, Pileczki V, Berindan-Neagoe I.

J BUON. 2018 May-Jun;23(3):692-705.

PMID:
30003739
16.

The foundation of personalized medicine is the establishment of biobanks and their standardization.

Policiuc L, Buse M, Gulei D, Andreea Zimta A, Braicu C, Iulia Irimie A, Berindan-Neagoe I.

J BUON. 2018 May-Jun;23(3):550-560.

PMID:
30003718
17.

In Vitro Transcriptome Response to a Mixture of Lactobacilli Strains in Intestinal Porcine Epithelial Cell Line.

Taranu I, Marin DE, Braicu C, Pistol GC, Sorescu I, Pruteanu LL, Berindan Neagoe I, Vodnar DC.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1923. doi: 10.3390/ijms19071923.

18.

Incognito: Are Microchimeric Fetal Stem Cells that Cross Placental Barrier Real Emissaries of Peace?

Cismaru CA, Pop L, Berindan-Neagoe I.

Stem Cell Rev. 2018 Oct;14(5):632-641. doi: 10.1007/s12015-018-9834-9. Review.

PMID:
29948753
19.

RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy.

Buduru S, Zimta AA, Ciocan C, Braicu C, Dudea D, Irimie AI, Berindan-Neagoe I.

Int J Nanomedicine. 2018 Jun 8;13:3397-3409. doi: 10.2147/IJN.S167383. eCollection 2018. Review.

20.

Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data.

Alexander-Dann B, Pruteanu LL, Oerton E, Sharma N, Berindan-Neagoe I, Módos D, Bender A.

Mol Omics. 2018 Aug 6;14(4):218-236. doi: 10.1039/c8mo00042e. Review.

21.

Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.

Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.

Crit Rev Clin Lab Sci. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25.

PMID:
29801428
22.

Decoding the Emerging Patterns Exhibited in Non-coding RNAs Characteristic of Lung Cancer with Regard to their Clinical Significance.

Sonea L, Buse M, Gulei D, Onaciu A, Simon I, Braicu C, Berindan-Neagoe I.

Curr Genomics. 2018 May;19(4):258-278. doi: 10.2174/1389202918666171005100124.

23.

The role of the pathology department in the preanalytical phase of molecular analyses.

Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Mihu CM, Berce C, Craciun L, Grewal R, Tomuleasa C.

Cancer Manag Res. 2018 Apr 12;10:745-753. doi: 10.2147/CMAR.S150851. eCollection 2018.

24.

Genetically enhanced T lymphocytes and the intensive care unit.

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.

Oncotarget. 2018 Mar 27;9(23):16557-16572. doi: 10.18632/oncotarget.24637. eCollection 2018 Mar 27. Review. Erratum in: Oncotarget. 2018 Aug 10;9(62):32097.

25.

Comparison of two models of inflammatory bowel disease in rats.

Catana CS, Magdas C, Tabaran FA, Crăciun EC, Deak G, Magdaş VA, Cozma V, Gherman CM, Berindan-Neagoe I, Dumitraşcu DL.

Adv Clin Exp Med. 2018 May;27(5):599-607. doi: 10.17219/acem/69134.

26.

Natural products with anti-aging potential: Affected targets and molecular mechanisms.

Cătană CS, Atanasov AG, Berindan-Neagoe I.

Biotechnol Adv. 2018 Nov 1;36(6):1649-1656. doi: 10.1016/j.biotechadv.2018.03.012. Epub 2018 Mar 27. Review.

PMID:
29597027
27.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

28.

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.

Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review.

29.

Current Insights into Oral Cancer Epigenetics.

Irimie AI, Ciocan C, Gulei D, Mehterov N, Atanasov AG, Dudea D, Berindan-Neagoe I.

Int J Mol Sci. 2018 Feb 27;19(3). pii: E670. doi: 10.3390/ijms19030670. Review.

30.

The Unforeseen Non-Coding RNAs in Head and Neck Cancer.

Irimie AI, Zimta AA, Ciocan C, Mehterov N, Dudea D, Braicu C, Berindan-Neagoe I.

Genes (Basel). 2018 Mar 1;9(3). pii: E134. doi: 10.3390/genes9030134. Review.

31.

Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.

Chira S, Gulei D, Hajitou A, Berindan-Neagoe I.

Trends Biotechnol. 2018 Jul;36(7):653-660. doi: 10.1016/j.tibtech.2018.01.014. Epub 2018 Feb 22. Review.

PMID:
29478674
32.

Implications of dietary ω-3 and ω-6 polyunsaturated fatty acids in breast cancer.

Zanoaga O, Jurj A, Raduly L, Cojocneanu-Petric R, Fuentes-Mattei E, Wu O, Braicu C, Gherman CD, Berindan-Neagoe I.

Exp Ther Med. 2018 Feb;15(2):1167-1176. doi: 10.3892/etm.2017.5515. Epub 2017 Nov 16.

33.

Protein dysregulation in graft versus host disease.

Qian L, Dima D, Berce C, Liu Y, Rus I, Raduly LZ, Liu Y, Petrushev B, Berindan-Neagoe I, Irimie A, Tanase A, Jurj A, Shen J, Tomuleasa C.

Oncotarget. 2017 Dec 15;9(1):1483-1491. doi: 10.18632/oncotarget.23276. eCollection 2018 Jan 2. Review.

34.

Exosomes-Small Players, Big Sound.

Gulei D, Irimie AI, Cojocneanu-Petric R, Schultze JL, Berindan-Neagoe I.

Bioconjug Chem. 2018 Mar 21;29(3):635-648. doi: 10.1021/acs.bioconjchem.8b00003. Epub 2018 Feb 9.

PMID:
29369619
35.

The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression.

Gulei D, Magdo L, Jurj A, Raduly L, Cojocneanu-Petric R, Moldovan A, Moldovan C, Florea A, Pasca S, Pop LA, Moisoiu V, Budisan L, Pop-Bica C, Ciocan C, Buiga R, Muresan MS, Stiufiuc R, Ionescu C, Berindan-Neagoe I.

Cell Death Dis. 2018 Jan 19;9(2):66. doi: 10.1038/s41419-017-0102-8.

36.

MiR-181 family-specific behavior in different cancers: a meta-analysis view.

Pop-Bica C, Pintea S, Cojocneanu-Petric R, Del Sal G, Piazza S, Wu ZH, Alencar AJ, Lossos IS, Berindan-Neagoe I, Calin GA.

Cancer Metastasis Rev. 2018 Mar;37(1):17-32. doi: 10.1007/s10555-017-9714-9.

PMID:
29327093
37.

CRISPR/Cas9: A Potential Life-Saving Tool. What's next?

Gulei D, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2017 Dec 15;9:333-336. doi: 10.1016/j.omtn.2017.10.013. Epub 2017 Nov 10. No abstract available.

38.

A Looking-Glass of Non-coding RNAs in oral cancer.

Irimie AI, Braicu C, Sonea L, Zimta AA, Cojocneanu-Petric R, Tonchev K, Mehterov N, Diudea D, Buduru S, Berindan-Neagoe I.

Int J Mol Sci. 2017 Dec 5;18(12). pii: E2620. doi: 10.3390/ijms18122620. Review.

39.

Genetic alterations in sporadic triple negative breast cancer.

Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I.

Breast. 2018 Apr;38:30-38. doi: 10.1016/j.breast.2017.11.006. Epub 2017 Dec 5.

PMID:
29202330
40.

Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?

Boca S, Berce C, Jurj A, Petrushev B, Pop L, Gafencu GA, Selicean S, Moisoiu V, Temian D, Micu WT, Astilean S, Braicu C, Tomuleasa C, Berindan-Neagoe I.

Med Hypotheses. 2017 Nov;109:42-45. doi: 10.1016/j.mehy.2017.09.023. Epub 2017 Sep 27.

PMID:
29150291
41.

Therapeutic potential of songorine, a diterpenoid alkaloid of the genus Aconitum.

Khan H, Nabavi SM, Sureda A, Mehterov N, Gulei D, Berindan-Neagoe I, Taniguchi H, Atanasov AG.

Eur J Med Chem. 2018 Jun 10;153:29-33. doi: 10.1016/j.ejmech.2017.10.065. Epub 2017 Nov 11. Review.

PMID:
29133056
42.

Targeting ncRNAs by plant secondary metabolites: The ncRNAs game in the balance towards malignancy inhibition.

Gulei D, Mehterov N, Nabavi SM, Atanasov AG, Berindan-Neagoe I.

Biotechnol Adv. 2018 Nov 1;36(6):1779-1799. doi: 10.1016/j.biotechadv.2017.11.003. Epub 2017 Nov 10. Review.

PMID:
29129653
43.

Molecular-trapping in Emulsion's Monolayer: A New Strategy for Production and Purification of Bioactive Saponins.

Obasi TC, Moldovan R, Toiu A, Braicu C, Bodoki E, Berindan-Neagoe I, Oniga I, Sandulescu R, Oprean R.

Sci Rep. 2017 Nov 6;7(1):14511. doi: 10.1038/s41598-017-15067-4.

44.

The new era of nanotechnology, an alternative to change cancer treatment.

Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I.

Drug Des Devel Ther. 2017 Sep 27;11:2871-2890. doi: 10.2147/DDDT.S142337. eCollection 2017. Review.

45.

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.

Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I.

Onco Targets Ther. 2017 Aug 28;10:4225-4238. doi: 10.2147/OTT.S137107. eCollection 2017.

46.

Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. A case report.

Frinc I, Dima D, Chitic M, Berce C, Berindan-Neagoe I, Tat T, Tanase A, Tomuleasa C, Bojan A.

Med Ultrason. 2017 Mar 14;19(3):330-332. doi: 10.11152/mu-976.

47.

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer.

Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I.

Int J Nanomedicine. 2017 Jun 26;12:4593-4606. doi: 10.2147/IJN.S133219. eCollection 2017. Review.

48.

Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.

Pop-Bica C, Gulei D, Cojocneanu-Petric R, Braicu C, Petrut B, Berindan-Neagoe I.

Int J Mol Sci. 2017 Jul 13;18(7). pii: E1514. doi: 10.3390/ijms18071514. Review.

49.

Low level of ochratoxin A affects genome-wide expression in kidney of pig.

Marin DE, Braicu C, Gras MA, Pistol GC, Petric RC, Berindan Neagoe I, Palade M, Taranu I.

Toxicon. 2017 Sep 15;136:67-77. doi: 10.1016/j.toxicon.2017.07.004. Epub 2017 Jul 6.

PMID:
28688805
50.

Nutrigenomics in cancer: Revisiting the effects of natural compounds.

Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I.

Semin Cancer Biol. 2017 Oct;46:84-106. doi: 10.1016/j.semcancer.2017.06.011. Epub 2017 Jul 1. Review.

PMID:
28676460

Supplemental Content

Loading ...
Support Center